Clinical Trial Update: Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and mechanism of radium-223 dichloride in combination with pembrolizumab in stage IV non-small cell lung cancer with bone …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Xofigo (radium-223 dichloride) (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: TERMINATED | Results posted: 2024-10-10